Evidence map›Paper›PMID 42553105›Full record

ArticleFrontiers in neurology

Longitudinal assessment of intraocular pressure in the 5xFAD mouse model of Alzheimer's disease.

Raz Rubinshtein, Basel Obied, Talal Salti, Andres I König, Alon Zahavi, Nitza Goldenberg-Cohen

Abstract read
In one paragraph

Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Raz RubinshteinOphthalmology Department, The Krieger Eye Research Laboratory, Bruce and Ruth Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel.
Basel ObiedOphthalmology Department, The Krieger Eye Research Laboratory, Bruce and Ruth Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel.
Talal SaltiOphthalmology Department, The Krieger Eye Research Laboratory, Bruce and Ruth Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel.
Andres I KönigOphthalmology Department, School of Neurobiology, Biochemistry and Biophysics, Tel-Aviv University, Tel Aviv, Israel.
Alon ZahaviDepartment of Ophthalmology and Laboratory of Eye Research, Rabin Medical Center, Petach Tikva, Israel.
Nitza Goldenberg-CohenOphthalmology Department, The Krieger Eye Research Laboratory, Bruce and Ruth Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Glaucoma and Alzheimer's disease (AD) are major neurodegenerative disorders with increasing evidence of shared pathogenic pathways. Glaucoma involves progressive optic nerve degeneration and irreversible vision loss, often associated with elevated intraocular pressure (IOP) but also occurring independently of it. AD, the leading cause of dementia, results in progressive cognitive and functional decline, with vision disturbances including visual field defects. Epidemiological studies report higher co-prevalence of glaucoma and AD in older adults. This study longitudinally assessed IOP in a transgenic AD mouse model to determine whether AD-related amyloid pathology inherently drives alterations in ocular pressure. Methods: Ten young (25 weeks old; 9 males, 1 female) and fifteen aged 5xFAD (57-60 weeks old; 5 males and 10 females) transgenic mice, a well-established amyloidogenic model of AD, were examined. Age-matched control groups included ten young wild type (WT) mice (9 males and 1 female) and fourteen aged WT mice (7 males and 7 females). IOP was measured repeatedly without anesthesia using a rebound tonometer (Icare Tonolab) calibrated for mice. Four IOP measurement sessions were performed at days 1, 36, 55, and 77, with all measurements conducted during midday hours (11:00-14:00) to minimize circadian variability. Results: IOP remained stable across most groups and time points. Aged 5xFAD mice exhibited transient, statistically significant fluctuations, characterized by an initial decrease at day 36 followed by a return to baseline levels. Age-matched WT mice showed no significant longitudinal changes. When comparing between groups, the only significant difference was observed at day 36, where aged 5xFAD mice demonstrated significantly lower IOP than aged WT controls. Conclusions: 5xFAD mice did not exhibit sustained IOP elevation compared with WT controls, with aged animals displaying only transient fluctuations that likely reflect physiological or measurement variability. These results suggest that amyloid-driven pathology in this model is not accompanied by chronic ocular hypertension. Consequently, our findings support the hypothesis that visual dysfunction in AD models may occur independently of elevated intraocular pressure, though the specific overlapping mechanisms between AD and glaucoma warrant cautious interpretation and further investigation.

Indexed as

5xFAD transgenic miceAlzheimer's diseaseglaucomaintraocular pressuremouse model

Identifiers

PMID42553105
PMCPMC13433196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.